2 recruiting, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow AZD5305: new trials by email Literature Review of AZD5305 trials Research Report on AZD5305
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone - Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 700 | 2025-08-06 | 2026-10-14 |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer Saruparib (AZD5305), Camizestrant, Abemaciclib - Advanced Breast Cancer | Phase 3 | Recruiting | AstraZeneca | 788 | 2024-08-01 | 2026-10-30 |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents Saruparib, Placebo, Abiraterone Acetate - Metastatic Castration-Sensitive Prostate Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1898 | 2023-11-21 | 2026-11-10 |
AstraZeneca (3)
Australia (3) · Austria (3) · Brazil (3) · Canada (3) · Chile (3) · China (3) · France (3) · Germany (3) · Hungary (3) · India (3) · Italy (3) · Japan (3) · Malaysia (3) · Peru (3) · Poland (3)
Arun Azad, MD (1) · Kim Nguyen Chi, MD (1)
2023 (1)